Background: We investigated treatment of unselected elderly patients with diffuse large B-cell lymphoma (DLBCL) and its subsequent impact on treatment tolerance and survival.
introduction
Hematopoietic and lymphoid tissue malignancies represent $7% of all new malignancies and deaths of malignancies in Europe [1] . Aggressive B-cell non-Hodgkin lymphoma (NHL) is the most common hematopoietic and lymphoid tissue neoplasm in adults in almost all populations worldwide and occurs frequently in elderly patients [2] . Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive B-cell NHL.
For patients with advanced-stage DLBCL, aggressive chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is the first choice of treatment [3, 4] . In the most recent decade, however, the addition of rituximab completes the standard treatment [5, 6] . Older patients receive chemotherapy less frequently. Moreover, dose intensity and the number of applied cycles has been described to be inferior as compared with younger patients [7] [8] [9] [10] . This may be caused by serious comorbidity, poor performance status and lower resilience [9] .
Since elderly are often not or only selectively included in clinical trials [11] [12] [13] [14] , evidence-based guidelines are mainly based on results of treatment in middle-aged relatively 'fit' patients. Management of cancer in elderly may need to be adapted in case of aggressive local or adjuvant and systemic treatment. In-depth studies with data from population-based cancer registries as a sampling frame should give insight into determinants of treatment and survival.
The aim of this study was to investigate treatment, treatment tolerance, motives for suboptimal treatment and outcome in elderly patients, aged over 75 years old, with advanced-stage DLBCL.
patients and methods study population and data collection
Population-based data from five regional Dutch cancer registries were used; these registries cover almost 8 million people and record data on patients newly diagnosed with cancer in all hospitals in their region, covering 38 community hospitals and 3 university hospitals. Trained registrars routinely collect data on patient and tumor characteristics, histology and Ann Arbor stage directly from the medical records. Furthermore, primary treatment (first 6 months) was registered as dichotomous variables (yes/no) for chemotherapy and radiotherapy. Additional data on comorbidity [Adult Co-morbidity Evaluation 27 (ACE-27) classification] [15] , World Health Organization (WHO) performance status [Eastern Cooperative Oncology Group (ECOG)], living alone, living independently, detailed information on treatment, and motives for no therapy, chemotherapeutical regimens, adaptations of treatment and underlying motives, response [16] and grade 3 or 4 toxicity (Common Terminology Criteria) [17] were gathered from the medical records by trained data managers. The ACE-27 index is a validated 27-item comorbidity index for patients with cancer. Information on 27 comorbid conditions was gathered from the medical records and classified as absent, grade 1 (mild decompensation), grade 2 (moderate decompensation) and grade 3 (severe decompensation). In case of two or more comorbid conditions, the highest grade was counted, and two or more grade 2 conditions were counted as grade 3. 'Living independently' also included patients who received home care. Patients living in institutions were classified as living dependently.
All patients aged ‡75 and diagnosed with advanced-stage DLBCL and recorded in the five regional population-based cancer registries between 1997 and 2004 were included (N = 419). DLBCL was classified according the WHO classification [18] . These neoplasms are documented from the medical records and registered in the cancer registry Follow-up was completed until 1st January 2009. In addition to passive follow-up via the hospital records, date of death or last contact was also obtained from the Municipal Personal Records Database (Gemeentelijke Basis Administratie). This institution collects data on vital status of all Dutch citizens. Survival time was defined as the time from diagnosis to death or end of the study. Patients who were alive at the end of the study were censored at 1st January 2009. For cause of death, data were merged with the database of Statistics Netherlands.
statistical analysis
Treatment of patients with advanced-stage DLBCL aged ‡75 was described. Patient characteristics were documented by subgroup of therapy: at least six cycles of CHOP-like chemotherapy, less than six cycles of CHOP-like chemotherapy, other (= suboptimal) chemotherapy, and no chemotherapy. CHOP-like chemotherapy was coded as CHOP, CHOP + rituximab (RCHOP), cyclophosphamide + hydroxorubicin + Vm-26 + prednisone + bleomycin + vincristine, and CHOP + methotrexate. Motives for suboptimal treatment and treatment adaptations were described. Furthermore, toxicity and response to treatment was reported per subgroup of therapy and age group.
Logistic regression was used to determine the independent effect of patient and tumor characteristics on the chance of receiving CHOP-like chemotherapy, and the chance of developing toxic effects and treatment adaptations from CHOP-like chemotherapy. Crude survival rates were computed. The independent effects of patient characteristics and treatment on survival were analyzed with Kaplan-Meier curves and Cox regression analysis. Multivariable survival analyses were carried out to estimate the hazard ratio (HR) of death. Cause of death was described, according to age, treatment adaptations and preexisting comorbidity.
Statistical analyses were carried out using SAS software (version 9.2, SAS Institute Inc., Cary, NC, 1999).
results
Of all 419 elderly advanced-stage DLBCL patients, 26 were excluded due to the fact that no additional data could be gathered because of missing or incomplete files. Furthermore, we excluded three patients who were diagnosed at autopsy and three patients who turned out to have an indolent NHL. The remaining 387 patients included in this study had a mean age of 81 years.
treatment of elderly DLBCL patients and characteristics associated with standard therapy Only 101 (26%) of the elderly patients received the standard therapy for at least six cycles of CHOP-like chemotherapy. Seventy-eight (20%) patients received less than six cycles CHOP-like chemotherapy, 17% received other (suboptimal) chemotherapy, and 36% received no chemotherapy. The percentage of patients receiving at least six cycles of CHOP-like therapy decreased from 36% of those aged 75-79 years to only 4% of patients aged >85 (Figure 1 ). Patient characteristics by subgroup of therapy are described in Table 1 . High age, comorbidity, poor performance status, elevated lactate dehydrogenase (LDH) levels, and low hemoglobin (Hb) levels were all associated with suboptimal or no chemotherapy. After adjustment for other variables, age and performance status were independently associated with receiving CHOP-like chemotherapy. In the investigated period, only 19 (11%) DLBCL patients received rituximab combined with their CHOP-like chemotherapy.
motives of suboptimal or no chemotherapy
Motives for suboptimal (other than CHOP-like) or no chemotherapy are listed in Table 2 . The most common reasons for withholding chemotherapy were refusal by patient/family (26%), poor performance status (19%) or estimated short life expectancy (13%). For suboptimal chemotherapy, these were high age (25%) or an unknown reason (37%).
adaptations of therapy and their motives
Seventy-three percent of all patients receiving CHOP-like chemotherapy could not complete the scheduled standard treatment. For most patients this was an adaptation in the number of chemotherapy cycles (52% complete at least six cycles). Furthermore, 12% had initial dose reductions and another 20% had dose reductions during treatment. Dose delays occurred in 22% of patients and the chemotherapeutical regimen was changed to a milder regimen in 9% of cases. In 53% of the cases, the motive for adaptation was toxicity, mostly hematological toxicity (Table 3) . After adjustment for other variables (sex, comorbidity, performance status, living independently, living alone, LDH and Hb level), age was the only factor associated with receiving less than six cycles of CHOP-like chemotherapy. toxicity and response to treatment Grade 3 or 4 toxicity occurred in 67% of patients receiving CHOP-like therapy but also in 40% of patients receiving milder regimens. In more detail, 36% of patients receiving CHOP-like therapy experienced hematological toxicity, 10% cardiovascular toxicity and 25% infections. Among patients receiving CHOPlike therapy, the percentage experiencing toxicity increased with age, from 62% in age group 75-79 years to 73% in patients aged 80-84 years, and 85% in patients aged ‡85 years. Toxicity also increased from 65% among those with high performance status to 83% among those with poor performance status.
Complete remission was achieved in 67% of patients receiving at least six cycles of CHOP-like chemotherapy and decreased toward 29% of those receiving less than six cycles. Complete remission rate was similar in all age groups. Of the patients with a complete remission after six or more cycles of CHOPlike therapy, 38% had a recurrence of disease in our study period, with a mean time between diagnosis and recurrence of 20 months. Thirty-three percent of patients receiving less than six cycles of CHOP-like therapy had a recurrence of disease after complete remission (time between diagnosis and recurrence was 16 months). Suboptimal chemotherapy resulted in a complete remission in 11% of the patients, of whom 63% had a recurrence of disease, with a mean time between diagnosis and recurrence of 16 months.
cause of death
Eighty-eight percent of all patients died during the study period. Cause of death was unknown in the medical records for 40% of all cases. One percent of the patients who received six or more cycles of CHOP died because of complications, but this proportion increased to 16% for those who could not complete at least six cycles.
Linkage with Statistics Netherlands showed us that 69% of deceased patients had died of their lymphoma, 14% of other cancer, 8% of cardiovascular diseases (CVDs), 3% of respiratory diseases and 7% of other causes. Elderly patients (>85) died more often of other cancers (13.8% versus 15.4%) and less often of CVDs (8.0% versus 5.6%). A higher number of patients with an adaptation of treatment died of NHL compared with patients without an adaptation of treatment (69% versus 51%). On the contrary, the patients without treatment adaptations died more often of other cancers (27% versus 10%). As expected, patients with cardiovascular comorbidity and diabetes had a higher percentage of cardiovascular-related deaths (11% versus 5% for CVD and 16% versus 6% for diabetes), and patients with COPD had a higher percentage of respiratory-related deaths (5% versus 2%). Treatment did not affect the chance of dying of NHL; 74% of the patients receiving CHOP-like chemotherapy died of NHL, and 75% of the patients receiving suboptimal or no chemotherapy died of NHL. Unfortunately, Statistics Netherlands does not identify difference between dying of the disease versus dying of the treatment.
survival Five-year overall survival was 18% for the total group of NHL patients. Overall survival by subgroup of therapy is shown in Figure 2 . Six months after diagnosis, 97% of patients who received six or more cycles of CHOP were alive. This percentage decreased to 58% of patients who received less than six cycles, 48% of patients receiving other chemotherapy and 24% of those not receiving chemotherapy. Five-year survival rates were 38%, 22%, 12% and 4%, respectively. For the total group of patients who started with CHOP chemotherapy, the original articles Annals of Oncology survival percentages after 6 months and 5 years were 80% and 31%, respectively.
Survival was negatively influenced by high age, advanced stage, comorbidity, poor performance status, low Hb levels, high LDH levels and suboptimal treatment. In multivariate analyses, high stage, comorbidity, poor performance status, elevated LDH and suboptimal therapy were independently associated with lower overall survival of elderly NHL patients (Table 4) . No statistical significant interaction between age and therapy was found. After correction for the age-adjusted International Prognostic Index (aaIPI) [19] , the effect of therapy (in four subgroups) was independently associated with survival (HR = 1.9, 1.6, and 4.7 for less that six cycles CHOP-like, other chemotherapy and no chemotherapy, respectively, compared to six or more cycles CHOP-like chemotherapy).
discussion
In daily practice, the application of standard therapy (CHOPlike chemotherapy) could be achieved in a minority of only 46% of patients aged ‡75 years. Not receiving chemotherapy was often due to refusal by patient/family, poor performance status or estimated short life expectancy. Of all patients receiving CHOP-like chemotherapy, only 56% could complete at least six cycles. The majority of patients receiving CHOP-like therapy suffered from severe toxicity (67% with grade 3 or 4), but this was also frequent (40%) in patients receiving milder regimens. Complete remission was achieved in 67% of patients receiving at least six cycles of CHOP-like chemotherapy, but 38% of these had a recurrence. The independent effect of therapy on survival remained after correction for the aaIPI. Life expectancy in elderly cancer patients is a function of age, disability and co-morbidity, along with the cancer type and stage. Therapeutic decision making involves a delicate balance among all these factors [7, 8, 15, [20] [21] [22] [23] . Therefore, treatment choice should be tailored to the individual patient. Our study confirms that in elderly patients, age, comorbidity, performance status, LDH levels and Hb levels all negatively influenced the choice for optimal cancer treatment with subsequent negative impact on survival. Furthermore, patient's refusal is also a prominent factor in treatment decisions (26%).
Earlier studies have shown that only 60%-80% of patients aged ‡60 years, with aggressive NHL, received chemotherapy [7, 8, 10] . Our study confirms this underuse of chemotherapy in those patients. Maartense et al. [8] showed that anthracycline-based chemotherapy was applied less frequently in elderly ( ‡70 years) patients (26%), and Thieblemont et al. [24] showed that only 4% of the patients aged ‡80 years received CHOP/RCHOP. The higher percentage (46% for age >75 and 34% for age >80) in our study is probably due to the fact that we studied only patients with DLBCL and a later period of study. In our study, monoclonal antibodies (rituximab) were only used in a rather small proportion of patients (5%). Therefore, we could not document the effect of this promising new therapy [25] in the older population. Further studies should investigate whether this small proportion of patients receiving rituximab is due to late introduction of this therapy or whether older patients are denied a possible successful therapy.
In our study, adaptations of treatment were often related to (hematological) toxicity and were needed in 73% of patients who were selected for CHOP-like chemotherapy. Physiological modifications of body function are known to occur with age and may interfere with cancer treatment, e.g. decreased bone marrow reserve, decreasing renal excretion, liver size, blood flow, albumin production, cytochrome P450 function and accumulation of body fat. These changes have important impact on the pharmacokinetic processes and can lead to potentially harmful consequences [21] [22] [23] . This is probably the cause of the high rate (67%) of grade 3 and 4 toxicity in our elderly population. However, despite the increased susceptibility of the elderly, dose of anticancer drugs is rarely adapted before chemotherapy is started [22] . In our study, 12% of the elderly had a dose reduction before start of chemotherapy. Older patients appear to be at higher risk for cardiotoxicity, hematological toxicity and infections [22] . Some threats may be prevented or reduced by proper supportive care, e.g. growth factors and prophylactic antibiotics. Others like cardiotoxicity, mucositis and neuropathy ask for special attention at each visit [21, 22] . In our study, age turned out to be associated with not being able to tolerate at least six cycles of CHOP-like chemotherapy. However, due to the retrospective nature of our study, we could not evaluate all factors that might be predictive for chemotherapy tolerance. This indicates that the selection of patients for toxic chemotherapy like CHOP needs to be improved. Comprehensive geriatric assessment (CGA) may be helpful for identifying which patients are at high risk for severe toxic effects [22, 27] . A major problem of CGA is that this is a time-consuming procedure and requires the availability of trained (geriatric) personnel. Recently, some attempts have been made to make shorter versions of CGA test, e.g. to make a preselection of possible frail patients [28, 29] . Furthermore, CGA should be validated for this specific patient group.
In our study 62% of the (>75) patients receiving at least six cycles of CHOP-like therapy achieved complete remission. This is in line with a Dutch study from the 80s reporting a CR rate of 57% of patients (age >75) who received chemotherapy including anthracyclin [8] and with Israel reporting a CR rate of 59% ( ‡80 years) [20] .
Our 5-year survival rates (18%) were in the lower end of the range of earlier (population-based and single institution) studies (18%-38%) [8, 24] . This is probably due to the higher age limit and selection of only DLBCL with advanced stage in our study. The following well-described patient-related variables may have an independent prognostic impact in elderly NHL patients: comorbidity, stage, performance status, Hb level and serum LDH level [7, 10, 19, [30] [31] [32] [33] . These factors were also related with poorer survival in our population. In previous studies, increasing age was also negatively associated with overall survival for patients with aggressive NHL [8, 10, 15, 32, 34] . This was also found in our univariate analyses, but after correction for stage, comorbidity, performance status, Hb level, LDH level and treatment, the prognostic effect of age disappeared. The negative influence of increasing age on overall survival in other studies could therefore be due to factors that correlate with age and for which we corrected. Although treatment is strongly related with the above-mentioned patient characteristics, the independent effect of therapy on survival remained after correction for the aaIPI. This study gives a rather unique insight into everyday practice, motives for treatment decisions, adaptations of treatment, toxicity and treatment outcome in unselected elderly NHL patients. However, we should keep in mind that this is a retrospective observational study in which there was selection of the fittest elderly for treatment. However, even in patients who were selected to be fit enough for undergoing CHOP-like chemotherapy, 44% could not complete at least six cycles. Furthermore, not all characteristics could be retrieved from the medical records. Some variables like performance status were often missing. In addition, Repetto et al. [27] suggested that activities of daily living and instrumental activities of daily living are more sensible than ECOG performance score alone and that many aspects of functional impairment are not fully recognized by ECOG performance score. Another limitation was the fact that we did not gather information about the use of medications. Therefore, we could not study the drug-drug interactions. However, use of medication generally has a high correlation with comorbidity. Unfortunately, we did not document whether patients received supplemental therapies. Supplemental therapies could have influenced dose intensity and the development of toxicities, and therefore have interfered with our results [35] . However, we expect the use of primary prophylaxis (with granulocyte colony-stimulating factor) to be low, because this treatment is not always covered by the Dutch healthcare insurance system. Prospective studies are needed not only for giving insight into the risks and benefits of treatment of this group of patients with a short life expectancy but also for evaluating the predictive value of patient characteristics. This would enable physicians and elderly patients to balance benefits, efforts and harm on a more individualized basis.
In conclusion, treatment of senior patients with advancedstage DLBCL proved to be complex and full of risks. Not only could standard therapy be applied less often with a subsequent independent negative impact on overall survival, the high toxicity rate and the impossibility of the majority of patients to complete treatment, implies that better treatment strategies should be devised including a proper selection of senior patients for this aggressive chemotherapy.
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